Browsing by Author "Aboushousha T."

Now showing 1 - 5 of 5

Comparative expression of RAGE and SOX2 in benign and malignant prostatic lesions
(Asian Pacific Organization for Cancer Prevention, 2019) Aboushousha T.; Lashen R.; Abdelnaser K.; Helal N.; Moussa M.; Omran Z.; Eldahshan S.; El Ganzoury H.; Department of Pathology; University of Modern Sciences and Arts; Giza; Egypt; Faculty of Biotechnology; University of Modern Sciences and Arts; Giza; Egypt; Department of Urorology; Theodor Bilharz Research Institute; Cairo; Egypt
Background: Prostate cancer (PCa) is a common health problem in elderly. RAGE (Receptor for advanced glycation end products) is overexpressed in multiple human cancers. SOX2 (Sex-determining region Y box 2) also functions as an oncoprotein and promotes cancer progression but the mechanisms involved remain largely unknown. Aim: The current study investigated the expression patterns of RAGE and SOX2 in benign and malignant prostate samples in correlation with the histopathological findings in order to evaluate their role as prognostic markers or therapeutic targets. Methods: Immunohistochemical staining for RAGE and SOX2 antibodies was applied on 87 prostatic biopsies [16 of prostatitis, 20 of benign prostatic hyperplasia (BPH) and 51 of PCa]. Results: Expression of RAGE and SOX2 (percentage of positive cells) was significantly higher in PCa lesions compared with prostatitis (p < 0.01) and BPH (p < 0.0001) and was also significantly higher in prostatitis compared with BPH lesions (p < 0.01). Also, percentage of positive RAGE and SOX2 cells showed a significant stepwise increase from Gleason Grade 3 to Grade 5 and were significantly higher in high Gleason Scores (?8) compared to lower Scores (?7) with statistical significance (p= 0.001). Conclusion: RAGE and SOX2 were up-regulated in prostate cancer lesions, mainly in advanced grades, suggesting an active role of both antigens in the development and progression of prostate cancer and expecting the possibility of their use as therapeutic targets. � 2019, Asian Pacific Organization for Cancer Prevention.
Differential expression of RAGE, EGFR and Ki-67 in primary tumors and lymph node deposits of breast carcinoma
(Wiley-VCH Verlag, 2018) Aboushousha T.; Hammam O.; Safwat G.; Eesa A.; Ahmed S.; Esmat M.E.; Helmy A.H.; Department of Pathology; Cairo university; Cairo; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts; Cairo university; Cairo; Egypt; Department of Pathology; Faculty of Medicine; Cairo university; Cairo; Egypt; Department of Surgery; Theodor Bilharz Research Institute; Cairo university; Cairo; Egypt
Background: Breast cancer is a complex disease that results from the inheritance of a number of susceptible genes. Intensive search wok was conducted world-wide on molecular bases of breast cancer in order to achieve the best therapeutic modalities; however, breast cancer still remains a challengeable task. It is very important to determine if the biological parameters in metastatic regional lymph nodes are similar to that in the primary breast cancer because therapy is indicated for patients with synchronous metastatic regional lymph nodes of breast cancer. Difference in therapeutic response in cases of breast cancer may be assumed partially to variability in the biological behavior of tumor tissue in primary breast cancer and lymph node metastasis. Aim: Our aim is to evaluate any variability in the expression of three types of tissue markers in both the primary breast tumors and corresponding axillary lymph nodes in order to expect the targeted therapeutic effect on both sites. Material and Methods: Three markers from different categories; RAGE, EGFR and Ki-67 were immunohistochemicalyl studied for their expression in biopsy specimens from primary breast tumors and their corresponding axillary lymph nodes. Results: There was a statistically significant difference in the expression of these markers between benign and malignant breast lesions.Although we found some differences in the expression of the three studied markers between primary breast cancer and corresponding axillary lymph nodes, yet these variations were mostly not statistically significant. Conclusion: Our findings support the validity of anti-RAGE and anti-EGFR therapy for treatment of both primary and nodal metastatic breast cancer in immunopositive cases. � 2018 Asian Pacific Organization for Cancer Prevention.
Evaluation of Mir-224, Mir-215 and Mir-143 as Serum biomarkers for HCV associated Hepatocellular carcinoma
(Asian Pacific Organization for Cancer Prevention, 2017) Mamdouh S.; Khorshed F.; Aboushousha T.; Hamdy H.; Diab A.; Seleem M.; Saber M.; Department of Biochemistry and Molecular Biology; Theodor Bilharz Research Institute; October University for Modern Sciences and Arts; Giza; Egypt; Department of Pathology; October University for Modern Sciences and Arts; Giza; Egypt; Department of Surgery; Theodor Bilharz Research Institute; October University for Modern Sciences and Arts; Giza; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts; Giza; Egypt; Department of Surgery; National Hepatology and Tropical Medicine Research Institute; Cairo; Egypt
HCV induced hepatitis and hepatocellular carcinoma as its sequel are major health problems world-wide and especially in Egypt. For diagnosis and during treatment of liver diseases, liver functions are monitored through determination of serum levels of liver enzymes and a-fetoprotein although the obtained information is generally not sufficient for either early detection of hepatic insult or effective follow up of therapeutic effects. More sensitive biomarkers may help to achieve these goals. MiRNAs are small non-coding RNAs that have an important role in gene expression and regulation. Many, such as miR-224, miR-215, miR-143 are correlated with tumor appearance and with the degree of fibrosis in lung, breast and colon cancer. This study was performed to estimate the level of these miRNAs in serum of patients with HCV-associated hepatitis and HCC in relation to grade of hepatitis, stage of fibrosis and differentiation of tumor tissue. In addition, correlations between serological and tissue levels were assessed. A total of 80 patients were examined, out of which 50 were included in the study. Blood samples and tissue specimens from malignant tumor and corresponding non-tumor tissue of HCV hepatitis patients were collected. Blood samples from 20 healthy volunteers were also obtained as controls. It was found that miRNAs profiles differed in HCC patients compared to controls and HCV-associated hepatitis cases. Distinction of tumor grade and fibrosis stage of patients as well as between different grades of tumor differentiation proved possible, making miRNAs promising biomarkers for diagnosis and assessment of treatment response of HCC patients.
Immunohistochemical and biochemical expression patterns of TTF-1, RAGE, GLUT-1 and SOX2 in HCV-associated hepatocellular carcinomas
(Asian Pacific Organization for Cancer Prevention, 2018) Aboushousha T.; Mamdouh S.; Hamdy H.; Helal N.; Khorshed F.; Safwat G.; Seleem M.; Pathology Departmenty; ; Giza; Egypt; Biochemistry Departmenty; ; Giza; Egypt; Surgical Department; Theodor Bilharz Research Institutey; ; Giza; Egypt; Faculty of Biotechnology; ; Giza; Egypt; National Hepatology and Tropical Medicine Research Institute; Cairo; Egypt
Objective: To investigate the expression of TTF-1, RAGE, GLUT1 and SOX2 in HCV-associated HCCs and in surrounding non-tumorous liver tissue. Material and Methods: Tissue material from partial hepatectomy cases for HCC along with corresponding serum samples and 30 control serum samples from healthy volunteers were studied. Biopsies were classified into: non-tumor hepatic tissue (36 sections); HCC (33 sections) and liver cell dysplasia (LCD) (15 sections). All cases were positive for HCV. Immunohistochemistry (IHC), gene extraction and quantitative real-time reverse-transcription assays (qRT-PCR) were applied. Results: By IHC, LCD and HCC showed significantly high percentages of positive cases with all markers. SOX2 showed significant increase with higher HCC grades, while RAGE demonstrated an inverse relation and GLUT-1 and TTF-1 lacked any correlation. In nontumorous-HCV tissue, we found significantly high TTF-1, low RAGE and negative SOX2 expression. RAGE, GLUT-1 and SOX2 show non-significant elevation positivity in high grade HCV compared to low grade lesions. TTF-1, RAGE and SOX2 exhibited low expression in cirrhosis compared to fibrosis. Biochemical studies on serum and tissue extracts revealed significant down-regulation of RAGE, GLUT-1 and SOX2 genes, as well as significant up-regulation of the TTF-1 gene in HCC cases compared to controls. All studied genes show significant correlation with HCC grade. In non-tumor tissue, only TTF-1 gene expression had a significant correlation with the fibrosis score. Conclusion: Higher expression of TTF-1, RAGE, GLUT-1 and SOX2 in HCC and dysplasia compared to non-tumor tissues indicates up-regulation of these markers as early events during the development of HCV-associated HCC.
Overview of MDM2 and B-RAF expression in gastric lesions
(Springer, 2018) Aboushousha T.; Helal N.; Hammam O.; Ibrahim M.; Khaled S.; Mostafa A.; Anas A.; Department of Pathology; Theodor Bilharz Research Institute; Imbaba; Giza; Egypt; Faculty of Biotechnology; October University of Modern Sciences and Arts; Giza; Egypt; Department of Surgery; Theodor Bilharz Research Institute; Imbaba; Giza; Egypt; Department of Hepato-Gastroenterology; Theodor Bilharz Research Institute; Giza; Egypt
BACKGROUND: Globally, gastric cancer (GC) it is the fourth most common cancer and the third cause of cancer-related deaths. Overexpression of MDM2 and B-RAF appeared to be increased in malignancy and associated with poor prognosis in several human tumours, but their role in gastric cancer remains controversial. AIM: We had investigated the immunohistochemical expression of MDM2 and B-RAF in 136 gastric lesions with/without H. pylori association. MATERIAL AND METHODS: Studied specimens include chronic gastritis (32), intestinal type GC (70), diffuse GC (22) and gastrointestinal stromal tumours (GIST) (12). RESULTS: MDM2 expression increased significantly in intestinal GC compared to other groups (p < 0.001), while B-RAF expression increased significantly in GIST compared to other groups (p < 0.001). H. pylori increased expression of MDM2 in intestinal GC cases but did not affect B-RAF expression. MDM2 expression correlated with high grade of tumor differentiation (p < 0.001), deep invasion (p < 0.05), nodal metastases (p < 0.05) and distant metastases (p < 0.1) in intestinal GC, while B-RAF expression did not correlate with TNM stage (p < 0.1). CONCLUSION: MDM2 up-regulation was more frequent in intestinal GC, while B-RAF up-regulation was more frequent in GIST compared to other groups; MDM2 expression in intestinal GC was correlated with H. pylori association, high grade of differentiation, deep invasion, nodal and distant metastases, meanwhile, B-RAF expression was correlated with high-grade intestinal GC but did not correlate with H. pylori or TNM stage. The possible role of both MDM2 and B-RAF in predicting progression of gastric tumours and prognosis deserves further investigations. 2018 Tarek Aboushousha, Noha Helal, Olfat Hammam, Manar Ibrahim, Samar Khaled, Amr Mostafa, Amgad Anas.